Differences in Survival Across Monogenic Forms of Parkinson Disease

Survival varied at a group level. What does it mean for patients?

Could survival in Parkinson disease (PD) depend on the causative gene, such as SNCA, PRKN, LRRK2, or GBA? To find out, investigators used data from the French Parkinson Disease Genetics Network national multicenter cohort. Subjects were genotyped for the presence of one of the four mutations. The national death register was used to document the endpoint.

Of 2037 database patients diagnosed with PD during a period of about 30 years, 889 died. Longer survival was associated with PRKN (n=100; hazard ratio, 0.41; P=0.001) and LRRK2 mutations (n=51; HR, 0.49; P=0.023) compared with those without one of the four mutations of interest. Shorter survival was associated with SNCA (n=20; HR, 9.88; P<0.001) and GBA mutations (n=173; HR, 1.33; P=0.048).

Reviewing Author

Michael S. Okun, MD

Disclosures

Consultant/Advisory BoardParkinson’s Foundation; Tourette Association of America

Speaker’s BureauMedscape/WebMD CME, Movement Disorders Society CME, American Academy of Neurology CME

RoyaltiesBooks4Patients; Demos; Cambridge; Taylor and Francis; Robert Rose; Public Affairs

Grant/Research SupportNational Institutes of Health; Parkinson’s Foundation; Tourette Association of America; University of Florida Foundation

Editorial BoardsTremor and Other Hyperkinetic Movements; JAMA Neurology

Leadership Positions in Professional SocietiesParkinson’s Foundation (Medical Advisor)